Atara Biotherapeutics/$ATRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Ticker
$ATRA
Sector
Primary listing
Employees
14
Headquarters
Website
ATRA Metrics
BasicAdvanced
$41M
1.94
$2.57
-0.40
-
Price and volume
Market cap
$41M
Beta
-0.4
52-week high
$19.15
52-week low
$3.92
Average daily volume
373K
Financial strength
Current ratio
0.818
Quick ratio
0.652
Long term debt to equity
-24.277
Total debt to equity
-26.947
Interest coverage (TTM)
13.05%
Profitability
EBITDA (TTM)
51.587
Gross margin (TTM)
61.79%
Net profit margin (TTM)
27.07%
Operating margin (TTM)
40.96%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$8,630,000
Management effectiveness
Return on assets (TTM)
47.81%
Return on equity (TTM)
-48.15%
Valuation
Price to earnings (TTM)
1.942
Price to revenue (TTM)
0.518
Price to book
-0.95
Price to tangible book (TTM)
-0.95
Price to free cash flow (TTM)
-1.229
Free cash flow yield (TTM)
-81.38%
Free cash flow per share (TTM)
-4.061
Growth
Revenue change (TTM)
-6.33%
Earnings per share change (TTM)
-122.52%
3-year revenue growth (CAGR)
23.85%
3-year earnings per share growth (CAGR)
-64.19%
10-year earnings per share growth (CAGR)
-26.51%
What the Analysts think about ATRA
Analyst ratings (Buy, Hold, Sell) for Atara Biotherapeutics stock.
ATRA Financial Performance
Revenues and expenses
ATRA Earnings Performance
Company profitability
ATRA News
AllArticlesVideos
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Newsfile Corp·3 days ago
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Business Wire·3 days ago
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atara Biotherapeutics stock?
Atara Biotherapeutics (ATRA) has a market cap of $41M as of April 05, 2026.
What is the P/E ratio for Atara Biotherapeutics stock?
The price to earnings (P/E) ratio for Atara Biotherapeutics (ATRA) stock is 1.94 as of April 05, 2026.
Does Atara Biotherapeutics stock pay dividends?
No, Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders as of April 05, 2026.
When is the next Atara Biotherapeutics dividend payment date?
Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Atara Biotherapeutics?
Atara Biotherapeutics (ATRA) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.